News
February 7, 2022
Nishimura & Asahi and FRONTEO hold "Economic Security Initiative
January 16, 2023
NEW YORK, January 16, 2023 – FRONTEO (TSE: 2158) has announced today that its proprietary AI engine "KIBIT" has successfully improved Japanese language processing in natural language processing.
April 30, 2021
Expanded the functions of the AI review tool “KIBIT Automator” which is a key to FRONTEO’s portfolio transformation, enabling one-stop handling of eDiscovery process from pre-processing to document review.
November 14, 2024
Accelerate indication identification and early licensing with FRONTEO’s unique technologies that systematically discovers unreported relationships between diseases and molecules from existing literature information.
September 9, 2022
U.S.-based lawyers with extensive experience explain the latest litigation cases and trends for Japanese companies
May 13, 2024
FRONTEO, Inc. (Head Office: Tokyo, Japan; Chief Executive Officer: Masahiro Morimoto; hereafter "FRONTEO"), Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi; hereafter "Shionogi"), and Suzuken Co., Ltd. (Head Office: Nagoya, Japan; President and CEO: Shigeru Asano; hereafter "Suzuken") are pleased to announce that we will collaborate with the aim of implementing the conversational dementia diagnosis support AI program in society.
April 11, 2023
Chat applications text, which has been used more due to the COVID-19 pandemic, can be analyzed
October 12, 2021
FRONTEO USA launched a new website on its Life Science business, which is drawing attention.
Under the title of “Equal Medical Care for Everybody with AI”, we introduce our AI system powered by “Concept Encoder”, the natural language analysis specialized in the Life Science fields below.
April 4, 2023
FRONTEO Will Discuss Leveraging AI in Cross-Border Forensics
November 25, 2019
November 2, 2021
KIBIT Automator, an AI-based e-discovery and digital forensics platform, runs on Microsoft Azure, the world's most secure environment.
November 12, 2024
FRONTEO, Inc. (Head Office: Minato-ku, Tokyo; President and CEO: Masahiro Morimoto; hereafter "FRONTEO") is pleased to announce that an agreement has been reached to provide Daiichi Sankyo Co., Ltd. (Head Office: Chuo-ku, Tokyo; President and COO: Hiroyuki Okuzawa; hereafter "Daiichi Sankyo") with analysis services using Drug Discovery AI Factory (hereafter "DDAIF")* to analyze text information from toxicity study databases and reports.
August 25, 2023
FRONTEO was thrilled to sponsor and attend ILTACON 2023, which was held this year in Orlando, FL, from August 20th through August 24th.
April 4, 2023
FRONTEO changes AI engine and product names to strengthen brand power and promote market penetration